Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Episode 26 • December 07, 2022 • 00:39:02
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.
Few & Far Between: How Biotech Gets Built
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Dec 07 2022 | 00:39:02

/

Show Notes

"Try to find the people who have a really strong background in regulatory science, who really understand the fundamentals, and who you believe can think creatively about the challenges of the cell therapy space." - Chris Min, Longeveron

Biorasi welcomes Chris Min to the Few & Far Between podcast for an inside look at the cell therapy industry and the importance of finding the right team to support your clinical trials. 

Other Episodes

Episode 16

December 15, 2021 • 00:58:27
Episode Cover

Episode 16: Dr. Alex Adjei, Scientific Advisory Board Member at Biorasi

Welcome to a special epsiode of Few & Far Between. Our guest this week is oncologist Dr. Alex Adjei, Scientific Advisory Board Member at...

Listen

Episode 71

May 12, 2026 • 00:43:24
Episode Cover

Episode 71: Chris O'Brien, Former ⁨Biorasi⁩ CEO and Current CEO of ⁨Rancho Biosciences

Today on the Biorasi Few & Far Between podcast: Join new host Melissa Alesse and former host Chris O'Brien - CEO at Rancho BioSciences...

Listen

Episode 40

April 25, 2024 • 00:33:23
Episode Cover

Episode 40: Professor Justin Stebbing, Editor-in-Chief, Oncogene journal

"I learned very early on that the stupidest cancer cell was cleverer than the cleverest oncologist." - Justin Stebbing, Editor-in-Chief of Oncogene, previously the...

Listen